Health Canada consultation on proposed vaping products promotion regulations
https://policybase.cma.ca/link/policy14128

POLICY TYPE: Response to consultation
DATE: 2020-01-20
TOPICS: Health care and patient safety, Population health, health equity, public health

Documents
Health Canada consultation on vaping products labelling and packaging regulations
https://policybase.cma.ca/link/policy14124

POLICY TYPE  Response to consultation
DATE  2019-09-05
TOPICS  Health care and patient safety
  Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125

POLICY TYPE  Response to consultation
DATE  2019-09-03
TOPICS  Health care and patient safety
         Population health, health equity, public health

Documents
Health Canada consultation on the impact of vaping products advertising on youth and non-users of tobacco products
https://policybase.cma.ca/link/policy14022

POLICY TYPE: Response to consultation
DATE: 2019-03-22
TOPICS: Health care and patient safety
Population health, health equity, public health

Documents
Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE  Response to consultation
DATE          2018-12-14
TOPICS        Health care and patient safety
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE       Response to consultation
DATE              2018-10-02
TOPICS            Health care and patient safety
                  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation

DATE  2018-04-23

TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dearest [Recipient],

The Canadian Medical Association (CMA) has the opportunity to participate in the consultation on the proposed front-of-package labelling for foods. The purpose of the consultation is to seek public feedback on the Draft White Paper on Front-of-package Labelling in Canada. The CMA, as a national physician-led organization, holds the health and well-being of Canadians as its top priority. We believe that labelling policies can have a significant impact on public health and the overall health of Canadians.

The CMA supports the inclusion of the proposed label on the front of packages, as it aligns with the principles of transparency and informed decision-making. The proposed label will provide clear and visible information about the nutritional content of food products, enabling consumers to make healthier choices and contribute to the reduction of preventable diseases.

In conclusion, the CMA encourages stakeholders to participate in the consultation and share their views on the proposed front-of-package labelling. We believe that this initiative has the potential to improve public health outcomes and enhance the well-being of Canadians.

Sincerely,

[Your Name]

Canadian Medical Association

[Date]
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE          Response to consultation
DATE                2017-04-05
TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Front-of-package labelling consultation
https://policybase.cma.ca/link/policy13800

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Health care and patient safety

Documents
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE: Response to consultation
DATE: 2016-10-31
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

Policy Type: Response to consultation
Date: 2016-08-12
Topics: Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of document content]

August 15, 2016

Dear Dr. [Name],

Chair, Plain Language and Policy Committee
Canadian Medical Association
360-920 King Street West
Toronto, ON M5V 1A8

I am writing to express my support for Health Canada’s consultation on “Plain and Standardized Packaging” and to share some thoughts on how this initiative could be further improved.

In recent years, there has been growing international interest in the concept of plain packaging, which involves removing graphical, textual, and branding elements from tobacco and pharmaceutical packaging to promote health and reduce the appeal of these products. Canada has been at the forefront of this movement, and I believe that similar approaches could be beneficial for other health-related products.

To encourage this initiative, Health Canada could consider the following measures:

- **Mandatory Reporting:** Implement a mandatory reporting system for pharmacists and healthcare providers to track the frequency and type of adverse drug reactions. This would help in identifying patterns and trends, allowing for targeted interventions to improve patient safety.
- **Consultation with Stakeholders:** Engage with a wide range of stakeholders, including healthcare professionals, patients, and industry representatives, to ensure that the proposed changes are informed and inclusive.
- **Evaluation and Monitoring:** Establish a system for evaluating the impact of plain packaging on patient behavior, medication adherence, and healthcare outcomes. This would help in refining the policy as needed.

I believe that with a well-structured approach, plain and standardized packaging can play a significant role in improving public health and patient safety. I look forward to seeing the results of Health Canada’s consultation and the potential outcomes of this initiative.

Sincerely,

[Your Name]

Canadian Medical Association
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE  2016-01-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE
Response to consultation

DATE
2014-08-26

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents